Clinical Trial Update: Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating single-agent temsirolimus (Torisel) in chemotherapy-naïve castration-resistant prostate cancer; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Torisel (Temsirolimus)

Snippet

Sponsor: Oncology Specialists, S.C. | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-04-07